
It took a significantly longer time for non-small lung cancer patients who received Roche’s Alecensa (alectinib) to have their disease progress than those who received chemotherapy, according to a Phase 3 clinical trial.
The results applied to ALK-positive non-small cell lung cancer (NSCLC) patients whose disease progressed after they were treated with platinum-based chemotherapy and Xalkori (crizotinib). The findings mean that the Phase 3 ALUR trial met its primary effectiveness objective.
“We are pleased to announce that the results of the phase III ALUR trial further support the use of Alecensa as a treatment for people with ALK-positive lung cancer who, after having progressed on both chemotherapy and crizotinib, are in need of new treatment options,” Sandra Horning, MD, Roche’s chief medical officer, said in a press release. “The results of this trial will support our access discussions with global health authorities as we seek to bring Alecensa to patients faster.”
Link para a notícia: Lung Cancer News Today







